glp-1 glp-2 glp-3 GLP-1, GLP-2, GLP-3, use them with intention Bispecific GLP-1/GLP-2 agonism in advanced

The most recent consensus algorithm released by the ADA/EASD lists GLP-1 analogues as a treatment option for consideration as a Tier 2 agent, or less well-validated therapy, in T2DM patients ( FIGURE 1 )

Discussion The results of this population based cohort study, designed to emulate a randomised controlled trial, suggest that the combined use of GLP-1 receptor agonists and SGLT-2 inhibitors is associated with a reduced risk of major adverse cardiovascular events and serious renal events, compared with using either drug class alone

Dereeper A, Audic S, Claverie JM, Blanc G

Interestingly, A1AT replacement therapy administered to patients with A1ATD has shown potential in reducing the risk of respiratory infections

A novel experimental model of MetALD in male mice recapitulates key features of severe alcohol-associated hepatitis